All In Biotech

Drug Trial Radar · NCT07612020

A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants

A Phase 1, Randomized, Open-Label Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector (Part A) and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus IV (Part B) in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Mar 16, 2026

Primary completion

Mar 2027

Study completion Oct 2027

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
May 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to see how the body reacts to empasiprubart, administered using an autoinjector (AI). The study will also look at other effects of empasiprubart, how it works in the body, and if it is safe. The study consists of 2 parts: parts A and B. In part A, eligible participants will be randomized to receive empasiprubart SC AI via abdomen, empasiprubart SC AI via thigh, or empasiprubart IV (intravenously). In part B, eligible participants will be randomized to receive empasiprubart SC AI via abdomen or empasiprubart IV. Participants from part A will be in the study for approximately up to 37 weeks . Participants from part B will be in the study for up to approximately 43 weeks.

Conditions

  • Healthy Volunteers

Interventions

  • empasiprubart SC AIBiological

    Subcutaneous injection of empasiprubart via Autoinjector (AI).

  • empasiprubart IVBiological

    Intravenous infusion of empasiprubart

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. aBA via abdomen as assessed by AUC0-inf SC versus AUC0-inf IVTime frame: Up to 33 weeks
  2. aBA via thigh as assessed by AUC0-inf SC versus AUC0-inf IVTime frame: Up to 33 weeks
  3. Ctrough at week 8Time frame: Up to 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences

    Mount Royal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.